Drug Pricing
Our work in Drug Pricing
-
Study Finds Consumer Copays Frequently Exceed Cost of Common Prescriptions
23 percent of claims analyzed in the sample involved an overpayment.
Categorized in -
Frequency and Magnitude of Co-payments Exceeding Prescription Drug Costs
Twenty-three percent of prescription claims analyzed involved a copay overpayment.
Categorized in -
Overpaying for Prescription Drugs: The Copay Clawback Phenomenon
In 2013, almost one quarter of filled pharmacy prescriptions (23%) involved a patient copayment that exceeded the average reimbursement paid by the insurer by more than $2.00.
Categorized in -
Prescription Drug Coupons: A One-Size-Fits-All Policy Approach Doesn’t Fit The Evidence
Schaeffer Center researchers discuss the complicated landscape of prescription drug copay coupons.
Categorized in -
Schaeffer Center Research Cited in Council of Economic Advisors’ Report on Drug Pricing
The report provides insight into the Administration’s drug pricing policy agenda.
-
Patient Cost-Sharing for Prescription Drugs: Policy Issues
The USC-Brookings Schaeffer Initiative for Health Policy will host a conference on the policy issues surrounding patient drug cost sharing. Two panels will convene, first to discuss restructuring the Medicare Part D benefit design, and then to debate the effectiveness of mechanisms to reduce cost sharing for commercially insured patients.
Categorized in -
Prescription Drug Copayment Coupon Landscape
The researchers examined copay coupon availability for the top 200 drugs (by spending) in 2014. Of these, 132 were brand drugs, and 90 of those had coupons available.
Categorized in -
This Is What’s at Stake if U.S. Drug Prices Fall — and Europeans Don’t Pay More
If pharmaceutical revenue increases, more money will go into R&D and new treatments
Categorized in -
Trump Said Global Drug Pricing Isn’t Fair – Schaeffer Research Explains Why
New white paper analyzes the global burden of medical innovation.
-
The Global Burden of Medical Innovation
Calculations using publicly available aggregate data suggest that the United States market accounts for 64% to 78% of worldwide pharmaceutical profits.
Categorized in